资金储备方面，截至2025年一季度末，君实生物货币资金及交易性金融资产余额合计约30.22亿元，充 足资金为后续高潜力管线快速推进提供保障。 目前，君实生物正在加快推进抗BTLA单.jpgcemalimab(TAB004/JS004)、抗IL-17A单抗(JS005)、PD- 1/VEGF双抗(JS207)等后期阶段管线的研发。早研管线亦储备不少潜在重磅产品，包括抗 Claudin18.2ADC(JS107)、PI3K-α口服小分子抑制剂(JS105)、抗CD20/CD3双特异性抗体(JS203)、抗 DKK1单抗(JS015)等早期阶段管线。君实生物计划于2025年推动多款管线进入关键注册临床。 今年3月，君实生物EGFR/HER3双抗ADC(JS212)获批临床。这是君实首个推进至临床阶段的双抗ADC 产品，也是全球第二个进入临床的EGFR/HER3双抗ADC。君实生物多项创新管线将在4月25日至30日期 间召开的2025AACR大会上"首秀"，其中DKK1抑制剂(JS015)用于胃肠道肿瘤的早期研究数据入选大 会"重磅研究"，Claudin18.2ADC(JS107)和创新双抗药物CD20×CD3双抗( ...

Financial Performance - The company's revenue for Q1 2025 was approximately ¥500.59 million, representing a year-over-year increase of 31.46% compared to ¥380.80 million in the same period last year[8]. - The net profit attributable to shareholders was a loss of approximately ¥234.88 million, an improvement from a loss of ¥283.03 million in the previous year[8]. - Total operating revenue for Q1 2025 reached ¥500,591,459.94, a 31.5% increase from ¥380,804,271.07 in Q1 2024[22]. - Net loss for Q1 2025 was ¥259,586,438.78, an improvement from a net loss of ¥299,647,965.46 in Q1 2024[22][23]. - Basic and diluted earnings per share for Q1 2025 were both -¥0.24, compared to -¥0.29 in Q1 2024[23]. Research and Development - Research and development expenses totaled approximately ¥350.58 million, accounting for 70.03% of the revenue, a decrease of 2.52 percentage points from the previous year[8]. - R&D expenses rose significantly to ¥350,575,453.92 in Q1 2025, compared to ¥276,292,124.92 in Q1 2024, marking a 27% increase[22]. - The company plans to accelerate the launch of multiple key registration clinical trials for early-stage pipelines by 2025, aiming to sustain revenue growth[17]. - The company has received approvals for clinical trial applications for JS212 and JS213, indicating ongoing development in its pipeline[17]. Cash Flow and Liquidity - The net cash flow from operating activities was a negative ¥24.33 million, an improvement from a negative ¥376.58 million in the same period last year[8]. - Cash flow from operating activities increased to ¥740,358,831.82 in Q1 2025, compared to ¥396,310,961.15 in Q1 2024, representing an increase of 86.7%[25]. - The company reported a significant increase in cash received from operating activities, indicating improved liquidity and operational efficiency[25]. - The ending cash and cash equivalents balance was $2.51 billion, down from $4.55 billion in the previous period[26]. Assets and Liabilities - Total assets at the end of the reporting period were approximately ¥10.90 billion, a slight increase of 1.07% from ¥10.78 billion at the end of the previous year[9]. - The total assets as of the latest reporting period amounted to ¥10,897,069,766.80, up from ¥10,781,960,410.10[20]. - Total liabilities increased to ¥5,227,909,703.20, compared to ¥4,849,830,645.95 in the previous period, reflecting a rise of 7.8%[20]. - The total equity attributable to shareholders decreased to ¥5,620,244,628.63 from ¥5,860,424,336.29, a decline of 4.1%[20]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 29,429[12]. - The total number of ordinary shareholders as of the reporting period was 29,429, with 29,420 being A-share ordinary shareholders[15]. - The top shareholder, HKSCC Nominees Limited, held 22.25% of the shares, totaling approximately 219.29 million shares[13]. Market and Product Development - The company plans to continue focusing on the commercialization of its pharmaceutical products to drive future revenue growth[11]. - The company's revenue growth was primarily driven by the sales of its core product, Toripalimab injection, which achieved sales revenue of approximately RMB 447 million, representing a year-on-year increase of about 45.72%[15]. - Toripalimab has been approved for 12 indications in mainland China, with 10 of these included in the national medical insurance catalog, enhancing its market accessibility[16]. - The company is focusing on enhancing its commercialization competitiveness through continuous global market expansion and operational management improvements[17].

上海君實生物醫藥科技股份有限公司 Shanghai Junshi Biosciences Co., Ltd.* ( 於中華人民共和國註冊成立的股份有限公司 ) 股份代號 : 1877 2024 年度報告 * 僅供識別 目錄 | 2 4 11 14 | 公司資料 摘要 主席報告 管理層討論及分析 | | --- | --- | | 59 | 董事、監事及高級管理層 | | 71 | 企業管治報告 | | 88 | 環境、社會及管治報告 | | 91 | 董事會報告 | | 113 | 獨立核數師報告 | | 117 | 綜合損益及其他全面收益表 | | 119 | 綜合財務狀況表 | | 121 | 綜合權益變動表 | | 123 | 綜合現金流量表 | | 126 | 綜合財務報表附註 | | 228 | 釋義 | 二零二四年年報 公司資料 執行董事 熊俊先生 （主席兼法定代表） 李寧博士 （副主席） 1 鄒建軍博士 （首席執行官兼總經理） 2 李聰先生 （聯席首席執行官） 張卓兵先生 姚盛博士 王剛博士14 李鑫博士 3 非執行董事 湯毅先生 馮輝博士 4 獨立非執行董事 張淳先生 馮曉源博士15 楊悅博士 ...

一、主要会计数据和财务指标 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 56490.16万股，累计占流通股比： 57.41%，较上期变化： -439.20万股。 | 名称 | 持有数量(万股) | 占总股本比例(%) | 增减情况(万股) | | --- | --- | --- | --- | | HKSCC NOMINEES LIMITED | 21929.12 | 22.29 | 不变 | | 熊俊 | 8785.40 | 8.93 | 不变 | | 上海檀英投资合伙企业(有限合伙) | 7145.93 | 7.26 | 不变 | | 苏州瑞源盛本生物医药管理合伙企业(有限合伙) | 4358.40 | 4.43 | 不变 | | 熊凤祥 | 4106.00 | 4.17 | 不变 | | 华夏上证科创板50成份ETF | 3025.34 | 3.08 | -505.06 | | 周玉清 | 2168.08 | 2.20 | 不变 | | 易方达上证科创板50ETF | 2158.33 | 2.19 | -86.91 | | 香港中央结算有限公司 | 1499.56 | 1.52 | 1 ...

证券代码：688180 证券简称：君实生物 公告编号：临 2025-026 上海君实生物医药科技股份有限公司 自愿披露关于特瑞普利单抗一线治疗黑色素瘤的 新适应症上市申请获得批准的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 近日，上海君实生物医药科技股份有限公司（以下简称"公司"）收到国家 药品监督管理局核准签发的《药品注册证书》，特瑞普利单抗（商品名：拓益®） 用于不可切除或转移性黑色素瘤的一线治疗的新适应症上市申请获得批准。这是 特瑞普利单抗在中国内地获批的第 12 项适应症。由于药品获得上市批准后的商 业化容易受到一些不确定性因素的影响，敬请广大投资者谨慎决策，注意防范投 资风险。现将相关情况公告如下： 一、药品基本情况 特瑞普利单抗注射液是中国首个批准上市的以 PD-1 为靶点的国产单抗药物， 曾荣膺国家专利领域最高奖项"中国专利金奖"，至今已在全球（包括中国、美 国、欧洲及东南亚等地）开展了覆盖超过 15 个适应症的 40 多项由公司发起的临 床研究。正在进行或已完成的关键注册临床研究在多个瘤种范围内评 ...

证券代码：688180 证券简称：君实生物 公告编号：临 2025-027 会议召开时间：2025 年 5 月 8 日（星期四）15:00-17:00 会议召开地点：上证路演中心（http://roadshow.sseinfo.com） 会议召开方式：网络文字互动 上海君实生物医药科技股份有限公司 关于参加 2024 年度科创板创新药行业集体业绩说明会 暨 2025 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资者可于 2025 年 4 月 28 日（星期一）至 2025 年 5 月 7 日（星期三） 16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过上海君实生 物医药科技股份有限公司（以下简称"公司"）邮箱 info@junshipharma.com 进 行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 公司已分别于 2025 年 3 月 28 日和 2025 年 4 月 26 日在上海证券交易所网 站（www.sse.com.cn）披露公司 20 ...

王雨舟女士联系方式： 证券代码：688180 证券简称：君实生物 公告编号：临 2025-025 上海君实生物医药科技股份有限公司 关于聘任证券事务代表的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海君实生物医药科技股份有限公司（以下简称"公司"）于 2025 年 4 月 25 日召开第四届董事会第八次会议，审议通过了《关于聘任证券事务代表的议 案》，同意聘任王雨舟女士为公司证券事务代表，任期自本次董事会审议通过之 日起至第四届董事会届满之日止。 王雨舟女士已取得上海证券交易所科创板董事会秘书资格证书，具备履行证 券事务代表职责所必需的专业知识、工作经验及相关素质，能够胜任相关岗位职 责的要求，其任职符合《中华人民共和国公司法》《上海证券交易所科创板股票 上市规则》等相关法律法规和规范性文件的规定。王雨舟女士的简历详见附件。 电话：021-61058800-1153 传真：021-61757377 邮箱：info@junshipharma.com 办公地址：上海市浦东新区平家桥路 100 弄 6 号 7 幢 1 ...

Financial Performance - The company's revenue for Q1 2025 was CNY 500,591,459.94, representing a 31.46% increase compared to CNY 380,804,271.07 in the same period last year[3] - The net profit attributable to shareholders was a loss of CNY 234,876,226.63, an improvement from a loss of CNY 283,029,082.76 year-over-year[3] - The net cash flow from operating activities was a negative CNY 24,331,196.50, significantly improved from a negative CNY 376,577,871.82 in the prior year[3] - Total revenue for Q1 2025 reached ¥500.59 million, a 31.5% increase from ¥380.80 million in Q1 2024[17] - Net loss for Q1 2025 was ¥259.59 million, an improvement compared to a net loss of ¥299.65 million in Q1 2024[18] - Basic and diluted earnings per share for Q1 2025 were both -¥0.24, an improvement from -¥0.29 in Q1 2024[18] Research and Development - R&D expenses totaled CNY 350,575,453.92, accounting for 70.03% of revenue, a decrease of 2.52 percentage points from the previous year[3] - Research and development expenses rose significantly to ¥350.58 million, up 27% from ¥276.29 million in the same period last year[17] - The company continues to focus on expanding its research and development efforts to enhance product offerings and market presence[22] Assets and Liabilities - Total assets at the end of the reporting period were CNY 10,897,069,766.80, a 1.07% increase from CNY 10,781,960,410.10 at the end of the previous year[4] - The company's total liabilities increased to RMB 5.228 billion from RMB 4.850 billion, indicating a rise in financial obligations[14] - The total equity attributable to shareholders decreased by 4.10% to CNY 5,620,244,628.63 from CNY 5,860,424,336.29[4] - The total equity attributable to shareholders decreased to RMB 5.620 billion from RMB 5.860 billion, showing a decline in shareholder equity[14] Market and Product Development - The company reported an increase in commercial drug sales, contributing to the rise in revenue[6] - The company's revenue growth during the reporting period was primarily driven by the sales of commercialized drugs, with the core product, Toripalimab injection (brand name: Tuoyi®/LOQTORZI®), achieving sales revenue of approximately RMB 447 million, representing a year-on-year increase of about 45.72%[10] - Toripalimab received conditional approval for routine use in treating unresectable or metastatic melanoma after previous systemic therapy failure, and a new indication for first-line treatment of advanced hepatocellular carcinoma in combination with Bevacizumab was approved[10] - During the reporting period, Toripalimab was approved for marketing by the Australian Therapeutic Goods Administration and the Singapore Health Sciences Authority, with 12 indications approved in mainland China, 10 of which are included in the national medical insurance catalog[11] - The company plans to accelerate the registration clinical trials for multiple products by 2025 and enhance the development and application of late-stage pipelines to ensure sustained revenue growth[12] - The company is committed to expanding its global market presence and increasing the accessibility of approved products and indications included in the national medical insurance catalog[12] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 29,429[8] - The top shareholder, HKSCC NOMINEES LIMITED, held 22.25% of the shares, totaling 219,291,210 shares[8]

Core Viewpoint - Junshi Biosciences has received approval from the National Medical Products Administration for toripalimab as the first-line treatment for unresectable or metastatic melanoma, marking its 12th indication in mainland China [1][8]. Group 1: Company Overview - Junshi Biosciences is an innovation-driven biopharmaceutical company focused on discovering, developing, and commercializing novel therapies, with a diverse R&D pipeline of over 50 drug candidates [12]. - The company has achieved significant milestones, including the approval of toripalimab, China's first domestically developed anti-PD-1 monoclonal antibody, in over 35 countries and regions [12][9]. - The company aims to provide world-class, trustworthy, affordable, and innovative drugs, with a mission of "In China, For Global" [13]. Group 2: Product and Clinical Study Insights - Toripalimab is an anti-PD-1 monoclonal antibody that blocks PD-1 interactions, enhancing the immune system's ability to target tumor cells [6]. - The supplemental NDA approval for toripalimab was based on the MELATORCH study, a Phase 3 clinical trial that demonstrated significant improvements in progression-free survival (PFS) and overall survival (OS) compared to dacarbazine [3][4]. - The MELATORCH study showed a median PFS of 2.3 months for toripalimab versus 2.1 months for dacarbazine, with a 29.2% reduction in disease progression or mortality risk [4]. Group 3: Market Context and Clinical Need - Melanoma is a highly aggressive cancer with a rising incidence rate in China, where traditional treatments have limited effectiveness [2]. - The approval of toripalimab addresses an urgent clinical need for first-line immunotherapy options in advanced melanoma, as no domestic anti-PD-1 monoclonal antibody had been previously approved for this indication [2][5]. - The results from the MELATORCH study are particularly relevant to Chinese patients, as the trial exclusively enrolled participants from China [5].

君实生物公告，2025年第一季度营收为5.01亿元，同比增长31.46%；净亏损2.35亿元，去年同期净亏损 2.83亿元。 ...